Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 16, 2019-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced
View HTML
Toggle Summary Acceleron Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 14, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it
View HTML
Toggle Summary Acceleron Announces Publication of Luspatercept Phase 2 Beta-Thalassemia Study Results in Blood
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2019-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the journal Blood has published results from the Phase 2
View HTML
Toggle Summary Acceleron to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that Habib Dable , President and Chief Executive Officer, will
View HTML
Toggle Summary Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 5, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias,
View HTML
Toggle Summary Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to placebo Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J.
View HTML
Toggle Summary Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in significant reduction of transfusion burden compared to placebo Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec.
View HTML
Toggle Summary Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 28, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration ( FDA ) has
View HTML
Toggle Summary Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 27, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will host a conference call and live audio webcast on Monday,
View HTML
Toggle Summary Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 26, 2018-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming
View HTML